NEW YORK - U.S. health regulators have again declined to approve proposed wider uses of Bayer AG and Johnson & Johnson's lucrative blood clot preventer Xarelto, the drugmakers said on Friday. The ...

LONDON (Reuters) - Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker. The company's blockbuster Xarelto ...

The negotiations with participating drug companies will occur in 2023 and 2024, and any negotiated prices will become effective beginning in 2026. President Biden released this statement: "When ...

Bayer AG (($BAYRY)) announced an update on their ongoing clinical study. Bayer AG, in collaboration with Janssen Research & Development, LLC, has ...

Medicare, the health insurance program for people over 65 years old, said it will start negotiating prices on 10 drugs, part of its mandate under the Inflation Reduction Act to lower prescription ...

The first 10 prescription drugs the federal government will negotiate under a new federal law were revealed Tuesday, launching a process that could deliver drug discounts by 2026. The batch of 10 ...

MUNICH, Aug 31 (Reuters) - Bayer AG is to accelerate the development programme for Xarelto, an anticoagulant that is its most important pipeline product, the German drugmaker said on Sunday. Sign up ...

CMS released its highly anticipated list of 10 drugs subject to Medicare price negotiations Tuesday, which includes popular blood clot prevention drugs Eliquis and Xarelto and diabetes drugs Jardiance ...

The discounts, agreed to after months of negotiations with drug manufacturers, range between 38% and 79% on the medication’s list price, which is the cost of medication before discounts or rebates are ...

The FDA approved Johnson & Johnson and Bayer’s anti-clotting drug Xarelto for the treatment of atrial fibrillation, according to a CBS News report. The makers of Xarelto wanted the FDA to approve a ...